PACAP-27 vs Omentin-1
Head-to-head comparison of PACAP-27 (Pituitary Adenylate Cyclase-Activating Polypeptide-27) and Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) — benefits, dosing, side effects, research data, and where to buy.
| Property | PACAP-27 | Omentin-1 |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Pituitary Adenylate Cyclase-Activating Polypeptide-27 | Omentin-1 (Intelectin-1, ITLN1) |
| Molecular Weight | 3158 Da | ~35 kDa |
| Half-Life | minutes | hours |
| Amino Acids | 27 | 313 |
| Typical Dose | Research-only: 0.1-1 nmol/kg | No approved human dose; research use only |
| Route | Intraperitoneal/Subcutaneous | IV|SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 220 | 82 |
| Research Status | Pre-clinical | Pre-clinical |
PACAP-27 Benefits
- ✓anti-apoptotic signaling
- ✓insulin secretagogue effect
- ✓reduced ER stress
- ✓islet cytoprotection
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
PACAP-27 Dosing
0.1-1 nmol/kg in animal studies|10-100 nM in vitro|research-only intermittent dosing
Omentin-1 Dosing
not established|not established
PACAP-27 Side Effects
- ⚠flushing
- ⚠hypotension at high exposure
- ⚠headache
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
PACAP-27
PACAP-27 has been repeatedly shown to support beta-cell survival through cAMP/PKA and related pathways. In experimental models it mitigates cytokine damage, preserves insulin content, and helps maintain islet viability.
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.